Cellectis SA (CLLS)
3.11
-0.07
(-2.20%)
USD |
NASDAQ |
Jun 11, 16:00
3.11
0.00 (0.00%)
After-Hours: 19:55
Cellectis Research and Development Expense (Quarterly) : 23.09M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 23.09M |
| December 31, 2025 | 19.62M |
| September 30, 2025 | 19.34M |
| June 30, 2025 | 18.67M |
| March 31, 2025 | 17.36M |
| December 31, 2024 | 15.36M |
| September 30, 2024 | 23.83M |
| June 30, 2024 | 23.52M |
| March 31, 2024 | 22.32M |
| December 31, 2023 | 25.53M |
| September 30, 2023 | 18.89M |
| June 30, 2023 | 22.17M |
| March 31, 2023 | 21.08M |
| December 31, 2022 | 21.43M |
| September 30, 2022 | 23.70M |
| June 30, 2022 | 25.43M |
| March 31, 2022 | 26.53M |
| December 31, 2021 | 32.37M |
| September 30, 2021 | 34.32M |
| June 30, 2021 | 31.15M |
| March 31, 2021 | 31.00M |
| December 31, 2020 | 23.36M |
| September 30, 2020 | 20.10M |
| Date | Value |
|---|---|
| June 30, 2020 | 22.86M |
| March 31, 2020 | 20.72M |
| December 31, 2019 | 30.32M |
| September 30, 2019 | 21.60M |
| June 30, 2019 | 25.42M |
| March 31, 2019 | 14.51M |
| December 31, 2018 | 21.27M |
| September 30, 2018 | 18.69M |
| June 30, 2018 | 18.04M |
| March 31, 2018 | 18.40M |
| December 31, 2017 | 20.70M |
| September 30, 2017 | 21.56M |
| June 30, 2017 | 18.61M |
| March 31, 2017 | 20.87M |
| December 31, 2016 | 20.13M |
| September 30, 2016 | 17.23M |
| June 30, 2016 | 22.05M |
| March 31, 2016 | 20.80M |
| December 31, 2015 | 17.55M |
| September 30, 2015 | 14.98M |
| June 30, 2015 | 11.69M |
| March 31, 2015 | 6.295M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 31.31M |
| Akari Therapeutics Plc | 1.457M |
| Amarin Corp. Plc | 4.020M |
| Grifols SA | 105.29M |
| Autolus Therapeutics Plc | 21.17M |